VistaGen Therapeutics, Inc. — Form 10-Q Summary
Reporting period: Fiscal quarter and nine months ended December 31, 2020 (quarter ended December 31, 2020). The filing was dated February 11, 2021. VistaGen is a clinical-stage biopharmaceutical company with no approved products and no product-sale revenue.
Financial performance and position
- Revenue: $313,600 for the quarter and $647,600 for the nine months, entirely sublicense revenue recognized under the AffaMed PH94B agreement. Comparable 2019 periods had no revenue. The company received a $5.0 million upfront payment; $4.352 million remained deferred at December 31, 2020.
- Loss: Quarterly net loss was $5.299 million, compared with $5.962 million a year earlier. Nine-month net loss was $11.723 million, down from $17.507 million. Net loss attributable to common stockholders was $5.652 million for the quarter and $12.760 million for the nine months, including Series B preferred dividends. Quarterly and nine-month loss per share were $0.07 and $0.19, versus $0.15 and $0.43, respectively.
- Operating expenses: Quarterly R&D increased to $3.496 million from $3.015 million, largely as PH94B and PH10 manufacturing and development advanced. Nine-month R&D declined to $7.586 million from $11.534 million, mainly because the AV-101 Elevate Study had been completed. G&A fell to $2.117 million for the quarter and $4.777 million for the nine months, versus $2.948 million and $6.004 million, respectively; prior-year quarterly and nine-month costs included $826,900 of noncash warrant-modification expense.
- Cash flow: Nine-month operating cash use was $6.792 million, down from $13.178 million. Investing cash use was $249,900. Financing provided $110.018 million, primarily from equity and preferred-stock offerings and warrant exercises. Cash increased by $102.976 million to $104.331 million.
- Liquidity and obligations: Current assets were $104.996 million and current liabilities $2.981 million; total liabilities were $15.460 million. Notes payable were $98,400, and operating lease liabilities totaled $3.798 million. Management said cash was sufficient to fund planned operations for well beyond the following 12 months, while noting continuing losses and potential need for further capital.
- Equity financing and dilution: The December public offering generated approximately $93.6 million net, including 63 million common shares and 2 million Series D preferred shares. The August offering generated approximately $12.9 million net. Common shares outstanding were 138.8 million at period end, compared with 49.3 million at March 31, 2020; 141.7 million were outstanding as of February 11, 2021.
Material changes and business developments
- AffaMed received an exclusive PH94B license for Greater China, South Korea and Southeast Asia. VistaGen received a $5.0 million upfront payment and may receive up to $172 million in development and commercial milestones plus royalties; future payments depend on successful development and sales.
- Management planned two pivotal Phase 3 studies of PH94B for acute treatment of social anxiety disorder, plus exploratory PH94B studies in other anxiety conditions. PH10 had completed an exploratory Phase 2A study, with Phase 2B preparation underway. AV-101 development was being considered in combination with probenecid.
- AV-101’s 2019 Phase 2 Elevate Study in major depressive disorder did not meet its primary endpoint versus placebo. The company reported it was well tolerated and attributed the lack of differentiation potentially to insufficient active-metabolite levels in the brain; the proposed AV-101/probenecid approach remained to be tested clinically.
- The Series D preferred stock is convertible at an initial rate of 23 common shares per preferred share, but conversion was contingent on stockholder approval to increase authorized common shares. The company scheduled a March 5, 2021 vote to raise authorization to 325 million shares. It stated that approval would trigger recognition of an estimated $23 million noncash beneficial-conversion charge in the quarter ending March 31, 2021, with no aggregate effect on cash or stockholders’ equity.
Outlook, risks and unusual items
- Management expected continued operating losses and negative operating cash flow as it advances its pipeline. Planned work included PH94B Phase 3 preparation, exploratory PH94B studies, nonclinical studies, and possible AV-101/probenecid Phase 1B development.
- COVID-19 had caused intermittent delays in active pharmaceutical ingredient deliveries and manufacturing, logistics and analytical work. Further disruption could delay trials and development.
- Key risks include clinical or regulatory failure, reliance on third-party manufacturers and research organizations, competition, patent and licensing uncertainty, and the possibility that additional financing may be unavailable or dilutive. The filing states there is no assurance of future AffaMed or Bayer milestones or of additional financing on acceptable terms.
- Two material weaknesses in internal control over financial reporting—segregation of duties and accounting-software functionality—remained identified. Management said it had begun planning remedial measures after quarter end. Management separately concluded disclosure controls were effective.
- No legal proceedings were reported. The PPP loan of $224,400 was voluntarily repaid in December 2020, with accrued interest, after the December offering.
Most important facts for investors to verify
- Whether stockholders approved the authorized-share increase required for Series D conversion, and the resulting dilution and accounting charge.
- Whether PH94B manufacturing and trial preparations progressed as planned, and whether COVID-19 or supply constraints affected trial timelines.
- Whether the AV-101/probenecid clinical program proceeded and how it addresses the prior Elevate Study’s failure to meet its primary endpoint.
- Actual cash burn and subsequent financing needs compared with management’s stated runway; milestone and royalty assumptions should not be treated as assured revenue.
- Progress in remediating the two material weaknesses in financial reporting controls.